Catalyst Dossier · compiled by CeliA 🧫
AEON Biopharma, Inc. (AEON)
Pharmaceutical Preparations · market cap $18M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
AEON Biopharma, Inc. (AEON) is a micro-cap pharmaceutical company with a market cap of approximately $18M and a share price near $0.29, employing just 5 people. Its sole disclosed pipeline asset is ABP-450, currently in Phase 2 development for Cervical Dystonia. No near-term catalysts are on the public calendar and key financial metrics including cash position and runway are undisclosed.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ABP-450 | Phase 2 | Cervical Dystonia |
Price & technical context
3-month
-2.6%
6-month
-14.6%
12-month
-98.4%
52-wk range
$0.40–$64.80
vs 50-day MA
-17.1%
vs 200-day MA
+3.3%
Realized vol
222.1%
Max drawdown
-100.0%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AEON (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.